Sign in
Active, not recruitingPhase 3

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

Key facts

Who runs it
Clinuvel, Inc.
Where
Alpharetta, Augusta, Baton Rouge, Birmingham, Cedar Park, Charleston, Charlottesville, Chicago, Cleveland, Dallas, Detroit, Fresno, Lee's Summit, Los Angeles, Miami, Minneapolis, Miramar, Palo Alto, Philadelphia, Rochester, Roseville, San Diego, Thompson's Station, Tyler, and Washington D.C., United StatesSee the 25 sitesAlso in 4 other countries, 6 sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
200 people, planned
Started
11 Oct 2023
Ended
Jun 2026
Type of study
Interventional, 2 groups
Treatments tested
  • Afamelanotide and NB-UVB Light
  • NB-UVB Light
Record updated
8 July 2025

Who can take part

Age
12 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Male and female patients with a confirmed diagnosis of generalized vitiligo with VASI≥3 of the body and VASI on the head and neck ≥0.3 including an F-VASI≥0.1
  • Stable or active vitiligo
  • Aged 12 or more
  • Fitzpatrick skin types III-VI

Who cannot take part

  • Treatment with NB-UVB phototherapy in the last three months prior to study start
  • Any other treatment for vitiligo within 30 days prior to the Screening Visit
  • Use of any prior and concomitant therapy which may interfere with the objective of the study
  • Allergy to afamelanotide or the polymer contained in the implant
  • History of melanoma or lentigo maligna
  • History of dysplastic nevus syndrome
  • Any malignant skin lesions
  • Presence of severe hepatic disease or hepatic impairment
  • Fitzpatrick skin types I-II
  • Extensive leukotrichia
  • Female who is pregnant or lactating
  • Female of child-bearing potential not using adequate contraceptive measures
  • Sexually active man with a partner of child-bearing potential who is not using adequate contraceptive measures
  • Extensive tattoos

Where in United States

Also in 4 other countries, 6 sites

  • Alpharetta, GeorgiaHospital not named in the registry
  • Augusta, GeorgiaHospital not named in the registry
  • Baton Rouge, LouisianaHospital not named in the registry
  • Birmingham, AlabamaHospital not named in the registry
  • Cedar Park, TexasHospital not named in the registry
  • Charleston, South CarolinaHospital not named in the registry
  • Charlottesville, VirginiaHospital not named in the registry
  • Chicago, IllinoisHospital not named in the registry
  • Cleveland, OhioHospital not named in the registry
  • Dallas, TexasHospital not named in the registry
  • Detroit, MichiganHospital not named in the registry
  • Fresno, CaliforniaHospital not named in the registry
  • Lee's Summit, MissouriHospital not named in the registry
  • Los Angeles, CaliforniaHospital not named in the registry
  • Miami, FloridaHospital not named in the registry
  • Minneapolis, MinnesotaHospital not named in the registry
  • Miramar, FloridaHospital not named in the registry
  • Palo Alto, CaliforniaHospital not named in the registry
  • Philadelphia, PennsylvaniaHospital not named in the registry
  • Rochester, New YorkHospital not named in the registry
  • Roseville, MinnesotaHospital not named in the registry
  • San Diego, CaliforniaHospital not named in the registry
  • Thompson's Station, TennesseeHospital not named in the registry
  • Tyler, TexasHospital not named in the registry
  • Washington D.C., District of ColumbiaHospital not named in the registry

About the trial

What the trial wants to find out

The CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone.

The 2 groups in the trial

  • Afamelanotide and NB-UVB LightTreatment being tested
  • NB-UVB LightOther group

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Vitiligo
Record updated
8 July 2025